Literature DB >> 15328418

Switching leukemia cell phenotype between life and death.

Steven J Tucker1, Colin Rae, Alison F Littlejohn, Andrew Paul, David J MacEwan.   

Abstract

Divergent life or death responses of a cell can be controlled by a single cytokine (tumor necrosis factor alpha, TNF) via the signaling pathways that respond to activation of its two receptors (TNFR1 and TNFR2). Here, we show that the choice of life or death can be controlled by manipulation of TNFR signals. In human erythroleukemia patient myeloid progenitor stem cells (TF-1) as well as chronic myelogenous leukemia cells (K562), granulocyte-macrophage colony-stimulating factor primes cells for apoptosis. These death-responsive cells show prolonged TNF stimulation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase, but no NF-kappaB transcriptional activity as a consequence of receptor-interacting protein degradation by caspases. Conversely, cells of a proliferative phenotype display antiapoptotic NF-kappaB responses that antagonize c-Jun N-terminal kinase and p38 mitogen-activated protein kinase stress kinase effects. These proliferative effects of TNF are apparently due to enhanced basal expression of the caspase-8/FLICE-inhibitory protein FLIP. Manipulation of the NF-kappaB, c-Jun N-terminal kinase, or p38 mitogen-activated protein kinase signals switches leukemia cells from a proliferative to an apoptotic phenotype; consequently, these highly proliferative cells die rapidly. In addition, sodium salicylate mimics the death phenotype signals and causes selective destruction of leukemia cells. These findings reveal the signaling mechanisms underlying the phenomenon of human leukemia cell life/death switching. Additionally, through knowledge of the signals that control TNF life/death switching, we have identified several therapeutic targets for selectively killing these cells. Copyright 2004 The National Academy of Sciencs of the USA

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328418      PMCID: PMC516498          DOI: 10.1073/pnas.0400949101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.

Authors:  S Kreuz; D Siegmund; P Scheurich; H Wajant
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2.

Authors:  Xiaoming Li; Yili Yang; Jonathan D Ashwell
Journal:  Nature       Date:  2002-03-21       Impact factor: 49.962

3.  Inhibition of JNK activation through NF-kappaB target genes.

Authors:  G Tang; Y Minemoto; B Dibling; N H Purcell; Z Li; M Karin; A Lin
Journal:  Nature       Date:  2001-11-15       Impact factor: 49.962

4.  Modulation by caspases of tumor necrosis factor-stimulated c-Jun N-terminal kinase activation but not nuclear factor-kappaB signaling.

Authors:  Alison F Littlejohn; Steven J Tucker; Ahmed A A Mohamed; Stephen McKay; Matt J Helms; Peter Vandenabeele; David J MacEwan
Journal:  Biochem Pharmacol       Date:  2003-01-01       Impact factor: 5.858

5.  NF-kappaB signals induce the expression of c-FLIP.

Authors:  O Micheau; S Lens; O Gaide; K Alevizopoulos; J Tschopp
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

6.  ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis.

Authors:  K Tobiume; A Matsuzawa; T Takahashi; H Nishitoh; K Morita ; K Takeda; O Minowa; K Miyazono; T Noda; H Ichijo
Journal:  EMBO Rep       Date:  2001-03       Impact factor: 8.807

Review 7.  Signal transduction by tumor necrosis factor and its relatives.

Authors:  V Baud; M Karin
Journal:  Trends Cell Biol       Date:  2001-09       Impact factor: 20.808

8.  Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways.

Authors:  O J Jupp; S M McFarlane; H M Anderson; A F Littlejohn; A A Mohamed; R H MacKay; P Vandenabeele; D J MacEwan
Journal:  Biochem J       Date:  2001-11-01       Impact factor: 3.857

Review 9.  TNF receptor subtype signalling: differences and cellular consequences.

Authors:  David J MacEwan
Journal:  Cell Signal       Date:  2002-06       Impact factor: 4.315

10.  Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8.

Authors:  Mariola Fotin-Mleczek; Frank Henkler; Dierk Samel; Monica Reichwein; Angelika Hausser; Ingela Parmryd; Peter Scheurich; Johannes A Schmid; Harald Wajant
Journal:  J Cell Sci       Date:  2002-07-01       Impact factor: 5.285

View more
  4 in total

1.  Inflammatory reactive oxygen species-mediated hemopoietic suppression in Fancc-deficient mice.

Authors:  Daniel P Sejas; Reena Rani; Yuhui Qiu; Xiaoling Zhang; Sara R Fagerlie; Hiroyasu Nakano; David A Williams; Qishen Pang
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

2.  Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis.

Authors:  Colin Rae; Susana Langa; Steven J Tucker; David J MacEwan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-23       Impact factor: 11.205

3.  Identification of the zinc finger 216 (ZNF216) in human carcinoma cells: a potential regulator of EGFR activity.

Authors:  Gabriella Mincione; Maria Carmela Di Marcantonio; Chiara Tarantelli; Luca Savino; Donatella Ponti; Marco Marchisio; Paola Lanuti; Silvia Sancilio; Antonella Calogero; Roberta Di Pietro; Raffaella Muraro
Journal:  Oncotarget       Date:  2016-11-15

4.  Enhanced identification and biological validation of differential gene expression via Illumina whole-genome expression arrays through the use of the model-based background correction methodology.

Authors:  Liang-Hao Ding; Yang Xie; Seongmi Park; Guanghua Xiao; Michael D Story
Journal:  Nucleic Acids Res       Date:  2008-05-01       Impact factor: 16.971

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.